Treatment of immunosuppressed subjects
US11701408B2 · kind B2 · utility
2Cited by
2References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 11, 2019 |
| Grant date | Jul 18, 2023 |
| Priority date | — |
| Expiry date | Oct 11, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An EL-15 super agonist (IL-15N72D:IL-15RαSU/IgG1Fc; N-803) increases circulating NK cells, effector memory and effector memory RA cells in post-allogeneic hematopoietic stem cell transplant patients (HCT). Methods of treatment include administration of N-803 to subjects in need of such treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.